First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid.

ABSTRACT:

Objective

This study aimed at estimating the cumulative incidence of antiepileptic drug (AED) treatment failure of first-line monotherapy levetiracetam vs valproic acid in glioma patients with epilepsy.

Methods

In this retrospective observational study, a competing risks model was used to estimate the cumulative incidence of treatment failure, from AED treatment initiation, for the two AEDs with death as a competing event. Patients were matched on baseline covariates potentially related to treatment assignment and outcomes of interest according to the nearest neighbor propensity score matching technique. Maximum duration of follow-up was 36 months.

Results

In total, 776 patients using levetiracetam and 659 using valproic acid were identified. Matching resulted in two

SUBMITTER: van der Meer PB 

PROVIDER: S-EPMC8251728 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature